Ocular Therap

Q2 FY2026 EarningsQ2 FY2026 delivered a beat on the bottom line with a GAAP EPS of -$0.35 versus the -$0.39 consensus, driven by narrower-than-expected operating losses ($82.1M actual vs. $91.2M expected). Total revenue of $13.5M slightly exceeded expectations by 2.06%, while the cash balance of $598.6M provides a robust runway into 2028. The primary catalyst remains the AXPAXLI NDA submission for wet AMD, which is on track for Q4 2026 following positive Phase 3 SOL-1 results and FDA alignment.